Time-to-market (TTM) for a drug is a critical performance metric in the pharmaceutical sector. Despite decades of scientific research and technological advancements, TTM has not significantly improved, leading to prolonged development cycles that diminish a drug’s market value and impact. Reducing TTM not only provides a competitive edge to pharmaceutical companies but also ensures faster access to innovative therapies for patients in need.

Several phases of drug development offer opportunities for accelerating TTM, such as target identification, target-disease mapping, and druggability predictions. Nevertheless, these efficiency gains do not guarantee success at the clinical trials stage. In fact, despite advancements in drug discovery stages, clinical trials remain the biggest bottleneck in drug development pipelines. With up to 90% of drugs failing at this stage, improving clinical trial success rates is the most pressing challenge.

To accelerate progress, the industry is embracing AI-driven clinical research as a solution to improve trial success rates, streamline workflows, and manage multi-modal data at scale.

 In this blog, we explore how AI and machine learning (ML) are reshaping clinical research, the  key challenges that come with its adoption, and how Elucidata’s AI-ready platform is at the forefront of providing scalable biomedical solutions to mitigate these challenges.

Clinical Trial Phases: A Quick Overview

Clinical trials are the cornerstone of drug development, ensuring that new therapies are both safe and effective before widespread use. As soon as a drug is designed and preclinically tested for efficacy and optimization on animal models, it is ready for the clinical trial phase. Typically, the clinical trial process is divided into four key phases, each serving a distinct purpose.

Phase I: Safety & Dosage Testing

The primary goal of this phase is to determine the safe dosage levels and identify side effects in a small group (20-100) of healthy volunteers. The focus is to evaluate key properties such as how the drug is absorbed, metabolized and excreted. 

Phase II: Efficacy Evaluation

The main aim of this phase is to assess whether the drug has the intended therapeutic effect by testing on hundreds of patients with the targeted condition. It is typically divided into phase IIa, to measure dose response, and Phase IIb to evaluate drug efficacy.

Phase III: Large-Scale Validation

In this phase, the new drug is compared against existing treatments or placebos, by conducting randomized, controlled, and often double-blind trials on thousands of patients. This stage helps establish clinical benefit and safety at scale, and its successful completion is required for regulatory approval from authorities such as the FDA and EMA.

Phase IV: Post-Market Surveillance

Even after approval, it is essential to track the drug’s performance in real-world settings to identify long-term side effects, safety concerns, and effectiveness across diverse populations. This step often involves real-world evidence (RWE) collection from patient records, insurance claims, and registries.

Challenges in Clinical Trials

Despite the structured approach described above, clinical trials are notoriously slow, costly, and prone to failure, primarily for the following reasons.

Study Design Challenges
Clinical trial success depends heavily on robust study design, yet many trials struggle with hindrances which ultimately contribute to high failure rates and extended timelines.

• Defining Clear & Measurable Endpoints
  Many trials fail due to poorly defined primary and secondary endpoints, which make it difficult to assess treatment efficacy. If endpoints are too vague, subjective, or difficult to measure, results become inconclusive, leading to wasted resources and missed opportunities to bring effective therapies to market.
• Suboptimal Patient Stratification
  Incorrect patient subgroup selection can lead to misleading trial results, reducing a study’s ability to detect treatment effects. Genetic, metabolic, and demographic variations must be considered to ensure that trial results are applicable to broader populations.
• Inefficient Trial Designs & Rigid Protocols
  Traditional clinical trials often follow fixed protocols that do not allow for real-time modifications based on emerging data. Adaptive trial designs which use interim results to adjust dosage, sample size, or study arms, can increase efficiency but are underutilized due to regulatory and logistical challenges.
  
  
• Placebo & Control Group Challenges
  Using placebos in life-threatening conditions raises ethical concerns, making it difficult to design randomized controlled trials (RCTs).

Patient Recruitment & Retention
Recruiting eligible participants is time-consuming, taking up nearly one-third of the total time of clinical testing. Manual identification using unstructured medical notes, as well as strict selection criteria keep many eligible participants out of testing groups. In fact, many clinical trials struggle to recruit a sufficient number of participants to achieve the statistical power necessary for meaningful and reliable results. 

Even after recruitment, high dropout rates extend trial durations and increase overall costs. Retention challenges arise due to long trial durations, logistical difficulties, and lack of patient engagement. Additionally, underrepresentation of diverse populations can impact drug effectiveness across demographics, leading to inequitable treatment outcomes and limiting the generalizability of trial results.

Data Fragmentation & Integration Issues
Clinical trials generate vast amounts of multi-modal data, including Electronic Health Records (EHRs), genomics, imaging, and patient-reported outcomes. However, these datasets are often stored in silos across different systems, making data harmonization and real-time access difficult.

Without AI-ready, harmonized datasets, inefficiencies arise in trial design, patient selection, and data analysis. As a result, many promising drugs fail due to poor patient stratification or inadequate biomarker-driven insights. The inability to efficiently integrate and analyze multi-source clinical data limits the predictive power of trials, contributing to the high failure rate in drug development.

Regulatory & Compliance Hurdles
Navigating complex global regulatory frameworks can significantly delay trial approvals. Researchers must document extensive patient data, often entering dozens of data fields per participant to comply with FDA, EMA, and ICH regulations. While ensuring data integrity, transparency, and auditability is critical, the manual processes involved in regulatory submissions are time-consuming and prone to errors.

Moreover, many clinical trials fail due to regulatory roadblocks, such as:

• Inconsistent trial endpoints that do not align with regulatory expectations.
• Limited RWE to support drug efficacy claims.
• Delays in adverse event reporting, leading to trial disruptions.

These inefficiencies add to the already high costs of clinical trials, making drug development financially unsustainable for many promising therapies.

AI-Powered Solutions for Clinical Trial Optimization

AI and data-driven technologies enable pharmaceutical companies to reduce time-to-market, increase trial success rates, and cut costs.

1. AI-Driven Trial Design & Optimization

Trial design is one of the most critical factors in determining clinical success. AI enhances study design by:

• Predictive Algorithms: AI models such as HINT (Hierarchical Interaction Network)^[3] and SPOT (Sequential Prediction of Trial Outcomes)^[4] analyze drug molecules, target diseases, and patient eligibility to forecast trial success and refine study protocols.
• AI-powered data extraction: GPT-4-based models extract safety and efficacy data from trial abstracts, aiding in the efficient design of new studies.

2. AI-Driven Patient Recruitment & Retention

AI improves patient recruitment through:

• AI-powered patient screening: AI analyzes past trial data to refine inclusion/exclusion criteria and automate patient screening, accelerating recruitment while reducing bias. AI also helps patients find clinical trials they may be eligible for more effectively.
• Digital Twins: Virtual replicas of patients simulate control groups, potentially reducing the number of control participants required. This is particularly useful for rare diseases with limited participants and helps mitigate ethical concerns in life-threatening conditions by reducing the need for placebo groups.
• Chatbots for engagement: AI-driven chatbots provide real-time responses to patient inquiries and predict dropout risks, improving retention rates.

3. Multi-Modal Data Integration & Harmonization

Clinical trials generate vast amounts of data across genomic sequencing, imaging, lab results, EHRs, and wearable devices. AI streamlines data integration by:

• Automated data harmonization: AI-driven engines standardize and structure disparate datasets for unified analysis.
• Knowledge graphs and semantic models: These tools link related biomedical entities, improving contextual understanding in clinical datasets.
• Federated learning: This allows AI models to be trained on decentralized datasets across multiple institutions without sharing raw data, ensuring secure collaboration while preserving patient privacy and regulatory compliance.

4. AI for Data Management & Predictive Modeling

Efficient data processing and predictive analytics play a vital role in trial success. AI enhances this by:

• Automated data collection: Companies like Taimei Technology use AI to automate case report form generation, reducing data entry errors and improving efficiency.
• Unstructured data processing: AI extracts key insights from unstructured medical records, enabling faster data analysis.
• AI-powered simulations: These models predict trial outcomes by analyzing historical data, helping refine trial design before execution.
• Omics-driven patient stratification: AI ensures that treatments are tested on the most relevant patient subgroups for higher success rates.

5. AI for Regulatory Compliance & Reporting

Regulatory compliance is a major hurdle in clinical trials, requiring extensive documentation, auditing, and quality checks. AI accelerates regulatory processes through:

• Automated compliance monitoring: AI-powered systems validate data in real time, ensuring adherence to FDA, EMA, and ICH regulations.
• Automated reporting: AI extracts key trial data from literature assisting in the preparation of regulatory submissions.
• AI-powered document analysis: These tools scan clinical reports and regulatory documents for faster review.

6. AI in Post-Market Surveillance & Pharmacovigilance

Tracking adverse effects post-approval requires continuous monitoring of real-world data. AI enhances this process by:

• NLP-driven signal detection: AI extracts adverse event signals from clinical notes, literature, and social media.
• Deep learning models: AI detects previously unknown drug interactions using RWE.
• Automated pharmacovigilance platforms: These tools streamline adverse event reporting, reducing manual review times.

Elucidata’s Role in AI-Powered Clinical Trials

Elucidata’s biomedical data solutions such as Polly Atlas, and the Harmonization Engine provide the AI-ready infrastructure needed to streamline clinical trials. By enabling multi-modal data integration, real-time analytics, predictive modeling, and regulatory compliance, Elucidata ensures that pharmaceutical companies can accelerate drug development with high-quality, standardized data.

AI-Ready Data for Trial Design & Predictive Modeling

Clinical trials rely on harmonized, multi-modal datasets for accurate patient stratification, biomarker discovery, and adaptive trial designs.

• Polly’s AI-powered infrastructure ensures datasets from genomics, imaging, clinical trials, and real-world data are analysis-ready for AI-driven trial optimization.
• Atlas enables real-time querying and analysis of structured datasets, helping researchers identify patient subgroups, refine clinical endpoints, and build adaptive study protocols.
• Elucidata supports foundation model training on multi-omics datasets, enabling more precise biomarker discovery and risk modeling.
• Large Language Models (LLMs) are used to extract clinical concepts from source data and publications, mapping them to regulatory standards such as ADaM, SDTM, and CDISC.

Scalable Data Integration, Secure AI Deployment & Compliance-Ready Infrastructure

Elucidata’s cloud-native platform enables real-time harmonization, integration, and processing of heterogeneous clinical trial datasets. By leveraging high-performance computing (HPC), AI-driven automation, and compliance-ready infrastructure, Polly ensures that clinical data is scalable, secure, and AI-ready.

• Polly’s Harmonization Engine processes over 5,000 samples weekly across more than 26 data modalities, extracting granular, transparent, and AI-ready datasets.
• Polly ingests structured and unstructured data from CROs, internal cloud systems, and public repositories (e.g., NCBI, ClinicalTrials.gov) using ETL pipelines and APIs, ensuring smooth cross-platform compatibility.
• Polly supports HIPAA, GDPR, and FDA/EMA-compliant data management, ensuring traceability, auditability, and regulatory transparency.
• Polly provides on-demand, scalable HPC resources for large-scale AI model training, predictive simulations, and real-time analytics.
• A dedicated QA team of more than 60 trained associates validates dataset accuracy, compliance, and standardization, delivering 99% accurate, analysis-ready data.
• Polly’s centralized, scalable infrastructure allows researchers, CROs, and regulatory bodies to collaborate in real time on harmonized datasets, improving trial efficiency.

Ensuring Data Security & Regulatory Transparency

Clinical trials generate vast amounts of sensitive patient data, and non-compliance with security protocols can cause regulatory delays or trial rejections. Polly is built with enterprise-grade data protection and transparency measures to mitigate these risks.

• All data in transit and at rest is encrypted using AES-256 encryption to prevent unauthorized access.
• Polly enforces strict access policies, ensuring only authorized users can retrieve or modify clinical datasets.
• Polly maintains detailed logs of data transformations and access events, supporting traceability and regulatory audits.
• Polly provides built-in checks for HIPAA, GDPR, and 21 CFR Part 11 compliance, ensuring data integrity and transparency for regulatory submissions.

The road ahead

AI is already improving trial design, patient recruitment, data integration, and regulatory compliance, but its future will be shaped by expanding regulatory acceptance, RWE adoption, and decentralized trials. Regulatory agencies like the FDA and EMA are increasingly relying on RWE for drug approvals, with AI improving real-time patient monitoring, predicting long-term drug safety risks, and accelerating post-market surveillance by detecting adverse events faster. AI is also enabling decentralized and adaptive trials, allowing remote patient monitoring via wearables and supporting dynamic trial adjustments based on interim results. However, widespread adoption will require greater AI explainability and regulatory trust, with a growing emphasis on interpretable models and standardized validation frameworks to ensure compliance and transparency.

As AI in clinical research continues to evolve, the integration of multi-modal data, foundation models, and federated learning will define the next phase of drug development. Companies that invest in scalable, AI-powered data solutions today will be positioned to accelerate time-to-market and drive clinical breakthroughs.

AI’s potential in clinical research is only as strong as the data that powers it. Elucidata delivers the scalable infrastructure and harmonized datasets needed to unlock AI’s full potential.

Get in touch today to explore how Elucidata’s AI-ready data solutions can transform your clinical research.

‍